Grifols, SA
GRF
ISIN ES0171996087 / Valor 30689493
Grifols, SA
UMushroom community rating:
About company
Grifols, SA is a leading global healthcare company that specializes in plasma-derived medicines, biopharmaceuticals, and solutions in transfusion medicine. The company is known for its innovative products and services that enable millions of patients around the world to lead more productive lives. Grifols is also involved in the agglutination technique to determine blood groups and transfusion compatibility studies, using gel as a reagent in columns on cards. Additionally, the company is engaged in the preparation of intravenous medicines for fluid therapy, contributing to the healthcare industry with its expertise and commitment to improving patient outcomes.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (02.10.2025):
Grifols, SA reported strong financial performance in the first quarter of 2025, demonstrating significant growth in revenues, adjusted EBITDA, and free cash flow. The company remains confident in its strategic plan and anticipates continued growth throughout the year.
Revenue Growth
Revenues increased by 7.4% constant currency to reach EUR 1,786 million in Q1 2025.
Adjusted EBITDA Rise
Adjusted EBITDA grew by 14.2% constant currency, amounting to EUR 400 million.
Free Cash Flow Improvement
Free cash flow improved by EUR 209 million compared to the same period last year.
Guidance for FY 2025
Grifols reaffirmed its guidance for the full year 2025, positioning itself for consistent growth.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
5184 M
Market cap (USD)
877,392
Daily traded volume (Shares)
9.186 / 9.04
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
